News Release
For immediate release
GliSODin®
Supplement Shown to be a Preventative Agent Against
Atherosclerosis in Individuals with Metabolic Syndrome
MORRISTOWN,
NJ (March 13, 2007) PL Thomas (PLT) today, in association with
Isocell, Paris, France, announced the results of a new study
using their exclusive dietary supplement ingredient, GliSODin®
in the European Annals of Allergy and Clinical Immunology.
GliSODin supplementation in combination with healthy diet
and lifestyle modifications significantly inhibited the
progression of cardiovascular risk factors compared to diet and
modifications alone.
Conducted at
the National Association of Preventative Medicine (ANPM), Paris,
the researchers demonstrated the preventative efficacy of
GliSODin at a preclinical stage.
The
three-year study included young adults (aged 40 - 46) with
high-risk factors for cardiovascular disease as evidenced by the
risk factors of metabolic syndrome. Key measurements included
are body mass index (BMI), blood pressure, antioxidant status
and intima media thickness (IMT) of the carotid artery.
Oxidative stress is a known risk factor to promote inflammation
and cardiovascular disease, and the measurement of IMT, or
thickening of the artery, via precise Ultrasound-B Imaging is
accepted internationally as a method to allow detection of the
early stages of arterial damage.
According to
Francois Vix, President of Isocell, the manufacturer of
GliSODin, “This study is very interesting in that it confirms
changes in diet and lifestyle can impact risk factors, but do
not reduce inflammation nor protect cardiovascular health –
suggesting once started, the inflammatory process will
continue.” “Further,” Vix continued, “Clearly supplementation
with GliSODin helps halt inflammation and also positively
impacts and may even regress previous damage.”
For the
first twelve months all subjects were given dietary (Lyon Heart
Diet) and lifestyle modifications with rigorous oversight by the
clinicians. As a result, minor improvements in BMI, blood
pressure and LDL cholesterol were realized. However, the
subjects’ antioxidant status did not improve and their intima
media thickness was considered too high for individuals in their
age bracket.
The subjects
where then divided into two groups for an additional two years,
with the control group continuing on the heart-healthy diet, and
the active group following the diet but also given 500mg
GliSODin daily. The control group showed no change in
antioxidant status over the two year period, while the GliSODin
group saw a significant improved antioxidant status with a
reduction in MDA, a measure of lipid oxidation, and increases in
serum superoxide dismutase and glutathione peroxidase,
the body’s potent endogenous antioxidants.
Further, the
control group experienced a slight but significant thickening in
carotid IMT indicating progression in inflammation, while the
GliSODin group showed a significant reduction in IMT thickness
by the end of the first year of supplementation and a highly
significant reduction by the end of the second year (p<.001).
This new
study builds upon previous research in humans. In a
double-blind, placebo-controlled clinical trial that was
published in
Free Radical Research2, September 2004,
researchers showed GliSODin supplementation protects cellular
DNA against induced oxidative damage. GliSODin was the only
supplement to show a protective benefit in this well established
model of oxidative stress.
Previous
published human and laboratory studies have shown GliSODin’s
effectiveness in protecting cells from oxidative stress by
activating the body’s production of its own antioxidants,
including SOD, catalase and glutathione peroxidase.
This
“internal antioxidant defense system” is necessary for the
elimination of the free radicals produced by oxidative stress,
resulting in tangible health benefits, including helping protect
cellular DNA from oxidative stress, inhibit photo-oxidative
stress in the sun-sensitive, inhibit lactic acid accumulation
under exercise, help restore normal levels of SOD, and
positively affect other significant markers of oxidative stress.
More
information on GliSODin is available at the research site
www.glisodin.org and
www.glisodininfo.com
Contact PL
Thomas: phone: 973-984-0900 fax: 973-984-5666
info@plthomas.com or
www.PLThomas.com.
International Contact: Francois Vix [33] 1 53 98 85 00
info@isocell.fr
About
GliSODin®
GliSODin is
patented and trademarked by Isocell, Paris, France.
www.GliSODin.com. It is available in North America as a
nutritional raw material exclusively from PL Thomas & Co.,
Morristown, NJ. Numerous in vivo and human studies support the
use of GliSODin in nutritional applications
About PLT
PL Thomas
& Co., a New Jersey-based ingredient supplier, offers fifty
years of innovation in securing reliable, high quality raw
materials for the food/functional food and nutrition industries.
1 Cloarec, et. al., “GliSODin®, a Vegetal
SOD with Gliadin, As Preventative Agent vs. Atherosclerosis, as
Confirmed with Carotid Ultrasound-B Imaging,” European Annals
of Allergy and Clinical Immunology V 39 (2) 2007
2Muth,
et. al. "Influence of an orally effective SOD on hyperbaric,
oxygen related cell damage,” Free Radical Research 38:9
(2004) pp. 927-932
# # #
|
